FRLN News and Press, Freeline Therapeutics Holdings plc From 03/24/22

Company to progress to second dose cohort in the MARVEL-1 study immediately, with first patient dosing expected in mid-2022 LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”...

LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that senior management will participate in the following virtual investor conferences: H.C. Wainwright Gene Therapy ...

LONDON, March 15, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), today announced the closing of the registered direct offering of its American Depositary Shares (“ADSs”) announced on March 1...

Freeline Therapeutics Holdings (NASDAQ:FRLN) has entered into a definitive agreement with Freeline’s majority shareholder, Syncona Portfolio Limited, a subsidiary of Syncona Limited, and certain other existing shareholders to purchase $26.1M of its American Depositary Shares, each repr...

LONDON, March 11, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitatin...

Freeline Therapeutics (NASDAQ:FRLN) said the first patient was dosed in its phase 1/2 B-LIEVE trial of FLT180a to treat hemophilia B, a genetic bleeding disorder caused by a deficiency in the clotting factor IX protein. The company said FLT180a uses a proprietary adeno-associated virus v...

On track to complete dosing of the first cohort and share initial data by the end of the first half of 2022 On track to start pivotal Phase 3 trial in 2023 LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company...

FLT190 well-tolerated with promising early efficacy in Fabry disease including sustained α-Gal A expression up to two years GALILEO-1, a first-in-human, open-label, international, multicenter Phase 1/2 clinical trial evaluating FLT201 in Gaucher di...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Freeline Therapeutics (NASDAQ:FRLN) granted three newly hired employees non-statutory options to purchase 66.4K of its shares. Each of the options has an exercise price of $1.18/share. The options have a maximum 10-year term and vest over a 4-year service period, with 25% of the award ve...